MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin (MacTEL-Supp)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by The Lowy Medical Research Institute Limited.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
The Lowy Medical Research Institute Limited
ClinicalTrials.gov Identifier:
NCT00568828
First received: December 5, 2007
Last updated: NA
Last verified: December 2007
History: No changes posted
  Purpose

Earlier investigations have detected low levels of macular pigment (MP) in the center of the fovea and a halo of MP at a higher eccentricity in persons with type 2 idiopathic juxtafoveal teleangiectasia (MACTEL)[Helb H-M, Charbel Issa P, Pauleikhoff D, Scholl HPN, Holz FG, MacTel-Study Group. Macular Pigment Density and Distribution in Patients with Macular Telangiectasia. ARVO Annual Meeting 2006, Fort Lauderdale, 30.04.-5.05.2006. Program # 5701/B795]. To date it is not known whether the total MP is reduced in MACTEL or whether even more MP accumulates at higher eccenticities compared to healthy probands. With the suggested study we aim to

  1. investigate Lutein and Zeaxanthin serum levels in MACTEL probands
  2. investigate and quantify MP at the posterior pole of MACTEL probands
  3. detect possible changes of MP concentration and distribution following supplementation with Lutein and Zeaxanthin

Condition
Macular Teleangiectasia
Macular Pigment

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Pilot Study to Evaluate the Changes of Macular Pigment Optical Density in Patients With Idiopathic Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin

Resource links provided by NLM:


Further study details as provided by The Lowy Medical Research Institute Limited:

Primary Outcome Measures:
  • Macular Pigment Optical Density [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 12
Study Start Date: December 2007
Estimated Study Completion Date: February 2008
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

12 patients with Macular Teleangiectasia

Criteria

Inclusion Criteria:

  • Different distribution of macular pigment in patients with known macular teleangiectasia

Exclusion Criteria:

  • No
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568828

Contacts
Contact: Daniel Pauleikhoff, MD 49-251-933080 dapauleikhoff@muenster.de

Locations
Germany
Dep. of Ophthalmology, St. Franziskus Hospital Recruiting
Muenster, Germany, 48145
Contact: Meike Zeimer, MD    49-251-933080    kpl-auge@muenster.de   
Sponsors and Collaborators
The Lowy Medical Research Institute Limited
Investigators
Principal Investigator: Daniel Pauleikhoff, MD Chairman Dep. of Ophthalmology, St.Franziskus Hospital, Muenster, Germany
  More Information

No publications provided

Responsible Party: Daniel Pauleikhoff MD, Dep. of Ophthalmology, St. Franziskus Hospital, Muenster, Germany
ClinicalTrials.gov Identifier: NCT00568828     History of Changes
Other Study ID Numbers: MacTEL Supplement
Study First Received: December 5, 2007
Last Updated: December 5, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by The Lowy Medical Research Institute Limited:
Macular Teleangiectasia
Macular Pigment

ClinicalTrials.gov processed this record on August 21, 2014